Sponsor:
ORIC Pharmaceuticals
Code:
NCT05413421
Conditions
Metastatic Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
ORIC-944
Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets
Apalutamide (Erleada™) 60 mg or 240 mg tablets
Darolutamide (Nubeqa®) 300 mg tablets
Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-02. This information was provided to ClinicalTrials.gov by ORIC Pharmaceuticals on 2025-08-11.